Important regulatory notice. TB-500 (a synthetic peptide fragment of thymosin beta-4) is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound. This page is a literature-context overview of the published research record on TB-500 in tissue-repair models. It is not personal-use guidance and Peptides Lab UK does not endorse any human or veterinary use of TB-500.
Quick research summary. TB-500 is a synthetic peptide that contains an active fragment from thymosin beta-4 (TB4), a naturally occurring protein implicated in cellular migration and angiogenesis in the published cell-biology literature. Most of the published TB-500 evidence comes from in-vitro and rodent-model work. Like BPC-157, TB-500 has not been advanced through the regulated drug-development pathway by a pharmaceutical sponsor, and large human clinical-trial data is not available. TB-500 also appears on the WADA Prohibited List for sport.
UK regulatory position
TB-500 has not received a UK marketing authorisation. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. TB-500 is also banned in WADA-accredited anti-doping testing for sport. UK retailers marketing TB-500 with claims of efficacy in injury repair or athletic recovery are operating outside both the medicines framework and the sport-testing framework.
What the cell-biology literature reports
Thymosin beta-4 has been studied for several decades in the published literature on cellular migration, angiogenesis and wound-repair biology. The synthetic TB-500 fragment is described as containing an active sequence from TB4. Cell-culture studies report effects on cellular migration, actin biology and angiogenesis-related gene expression. These are biochemistry observations in cell-culture systems and do not translate one-for-one to human outcomes.
What the rodent-model literature reports
Rodent-model studies report protocol-defined endpoints in tissue-repair contexts. As with BPC-157, doses, routes and time courses vary widely between protocols and are study-specific. Independent reviewers note that rodent-model findings have not been replicated in published large human clinical trials.
WADA and sport-testing context
TB-500 appears on the WADA Prohibited List under the peptide hormones, growth factors, related substances and mimetics class. WADA-accredited laboratories run targeted assays for TB-500 and related compounds. Anyone competing under WADA, UK Anti-Doping (UKAD), professional federation rules or military testing should treat TB-500 as an analytically detectable banned substance.
For laboratory researchers
TB-500 is used as a research reference compound in in-vitro and small-animal model work. Quality requirements for any research-grade reference sample are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling. Peptides Lab UK supplies TB-500 on that basis.
Frequently Asked Questions
Is TB-500 licensed in the UK?
No. TB-500 has not received MHRA, EMA or FDA marketing authorisation.
Is TB-500 banned in sport?
Yes. TB-500 is on the WADA Prohibited List and WADA-accredited laboratories run targeted assays for it.
What does the published research describe?
Predominantly in-vitro cell-biology work and rodent-model tissue-repair studies. Published large human clinical-trial data is not available.
Where can I read the source literature?
PubMed indexes the peer-reviewed thymosin beta-4 and TB-500 literature.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. TB-500 is also a banned substance in sport under the WADA Prohibited List.
